

ASX RELEASE (ASX: MDR)

## Successful Completion of Share Purchase Plan

Melbourne, Australia, 15 May 2025 - Global pharmacy-driven patient engagement company, MedAdvisor Limited (**MedAdvisor Solutions** or the **Company**), is pleased to announce the successful completion of its Share Purchase Plan Offer (**SPP**).

On 1 April 2025, MedAdvisor Solutions announced the successful completion of a placement to institutional and sophisticated investors (**Placement**) raising A\$5 million (before costs) at a price of A\$0.10 per share. The Company also announced the launch of the SPP to enable existing shareholders to participate on the same terms as investors in the Placement.

As indicated in the Company's 1 April 2025 ASX announcement and the SPP Offer Booklet, the SPP was targeting proceeds of up to A\$2m (before costs), with each eligible shareholder allowed to subscribe for up to A\$30,000 new shares (**SPP Shares**) at A\$0.10 per share. The Company reserved the right to accept oversubscriptions.

The Company has received valid SPP applications totalling A\$2.668m.

The Board acknowledges and appreciates the support provided by shareholders through applications to participate in the SPP and on that basis, will accept all valid applications received.

The SPP Shares will be issued on Friday, 16 May 2025, and will rank equally with existing MedAdvisor fully paid ordinary shares on issue. Normal trading of the SPP Shares will take place on Friday, 16 May 2025.

CEO and Managing Director, Rick Ratliff said, "I wish to thank MedAdvisor shareholders for their support by way of participation in the SPP. The funds raised support the continued execution of our strategic and cost optimisation initiatives and provide additional working capital to drive sustainable growth. I look forward to updating shareholders on our progress."

## **EGM**

The Company notes that the Placement included an amount of \$375,000 committed by MedAdvisor Directors with the issue of the shares being subject to shareholder approval at an Extraordinary General Meeting. The Company advises that it expects to hold the Extraordinary General Meeting (**EGM**) on Friday, 27 June. Further details regarding the EGM will be provided in the Notice of Meeting.

- ENDS -

*This document has been authorised for release by the Managing Director and CEO of MedAdvisor Limited.*

### **For more information please contact:**

#### **Company**

Ancila Desai

Chief Financial Officer and Company Secretary

[corporate@medadvisorsolutions.com](mailto:corporate@medadvisorsolutions.com)

1300 125 343

#### **Investor Relations**

George Kopsiaftis

IR Department

[george.kopsiaftis@irdepartment.com.au](mailto:george.kopsiaftis@irdepartment.com.au)

+61 409 392 687

**About MedAdvisor Solutions**

*MedAdvisor Solutions (ASX: MDR) is a global leader of pharmacy-driven patient engagement solutions that provide personalised patient experiences to help simplify the patient medication journey. Leveraging THRiV, a cloud-based, AI enabled platform, MedAdvisor Solutions empowers the pharmacy of the future through improved pharmacy workflow and patient engagement solutions. MedAdvisor Solutions works with over 34,000 pharmacies across the US with reach to over two-thirds of the population. In Australia, more than 95% of Australian pharmacies use MedAdvisor Solutions software to improve pharmacy workflow and to connect with over 3.7 million patients. For more information, please visit: [medadvisorsolutions.com/investors](https://medadvisorsolutions.com/investors).*